# Sargramostim Use in COVID-19 to Recover Patient Health

> **NCT04707664** · PHASE2 · COMPLETED · sponsor: **Partner Therapeutics, Inc.** · enrollment: 600 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection

## Interventions

- **DRUG:** Sargramostim
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04707664
- **Lead sponsor:** Partner Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-27
- **Primary completion:** 2021-12-28
- **Final completion:** 2022-01-31
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2023-02-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707664, "Sargramostim Use in COVID-19 to Recover Patient Health". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04707664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*